Satipharm Commences Sale of Medicinal Cannabis Capsules to …

VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) — Harvest One Cannabis Inc. (TSXV:HVST) (“Harvest One” or the “Company“) through its wholly owned Swiss subsidiary, Satipharm AG (“Satipharm“), is pleased to advise that it’s Melbourne-based distribution partner, HL Pharma Pty Ltd (“HL Pharma”), has commenced distribution of Satipharm’s Gelpell-CBD™ capsules to approved patients in Australia.

Key developments:

  • Melbourne-based distribution partner HL Pharma commences distribution of Satipharm’s Gelpell-CBD™ capsules to approved patients in Australia

  • Gelpell-CBD™ capsules are one of the first medicinal cannabis products available to approved patients in Australia

  • Delivery of first products to Australian patients solidifies Australian market position and provides foundation for near-term revenue growth 

The commencement of Satipharm sales in Australia is part of a comprehensive strategy to expand the international distribution of its products for commercial and clinical research purposes. Satipharm is focused on developing cutting-edge dose delivery technology for pharmaceutical-grade cannabis products providing physicians

... read more at: https://globenewswire.com/news-release/2017/11/14/1185948/0/en/Satipharm-Commences-Sale-of-Medicinal-Cannabis-Capsules-to-Australian-Patients.html

by

Leave a Reply

Your email address will not be published. Required fields are marked *